A weekly trade journal catering to the Indian chemical industry
backBack

calendar 11 April, 2025 17:11:20 IST

Switzerland’s Novartis lines up $23-bn investment to boost US footprint

Article image

Swiss pharma giant, Novartis, has unveiled plans to invest $23-bn over the next five years in US-based infrastructure, to ensure all its key medicines for US patients will be made in the US. The company said it will establish a research hub in San Diego, expand three US plants and build seven new ones.

The production capacity will cover both active pharmaceutical ingredients (API) and biologics drug substance, as well as secondary production and packaging. The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the US outside of Novartis, the company said.

The announcement comes in the backdrop of potential tariffs on drugs imported into the US. Even though pharmaceuticals were exempted from tariffs, industry officials are still preparing for them at some point.

Over the next five years, Novartis said it will:

  • Establish one biomedical research innovation hub in San Diego, its second global R&D hub in the US. The planned $1.1-bn San Diego research hub, expected to open between 2028 and 2029, will serve as the epicentre of the Novartis West Coast Biomedical Research presence, complementing existing hubs in Cambridge, MA, and Basel, Switzerland.
  • Build four new manufacturing facilities in soon-to-be-determined states, including three that will make biologics drug substances, drug products, device assembly and packaging, and one facility that will make chemical drug substances, oral solids dosage forms and packaging
  • Build two new radioligand therapy (RLT) manufacturing facilities in Florida and Texas
  • Expand three RLT manufacturing facilities in Indianapolis, Millburn, and Carlsbad

With these investments, Novartis will have manufacturing capacity in the US for all its core technology platforms, including small molecules and biologics.

This new investment will bring internal manufacturing of the company’s siRNA technology to the US for the first time.

“The US is a priority market for Novartis, and the company has taken numerous steps over its 200-year history to build its US infrastructure. Over the next 5 years, the total investment in Novartis US operations is expected to be nearly $50-bn, marking a clear demonstration of the company’s focus on the US,” the company emphasised in a press note.

article image
calender image

calender image 2 November, 2026 18:04:08 IST

AI for supply chain resilience in chemicals is here

Chemical supply chains now operate as “integrated decision networks,” where production planning, demand forecasting, inventory optimisation, transportation capacity, po...
article image

calender image 6 November, 2026 16:01:05 IST

Grasim, Suzlon team up to pilot chemically recyclable wind turbine blades

Mumbai-based Grasim Industries, a diversified Aditya Birla Group company with businesses in cellulosic fibres, chemicals and...

PRINT EDITION

View Past Issues

Search For

Exhibitions & Conferences

ChemExpo IndiaChemProTechChemLogistics India

Watch

KKBangEchemiAPi ChinaGPCA ForumCPHI PMEC INDIA